The longevity economy spent its first decade with two centers of gravity: the diagnostic-driven clinics of California and the Alpine medical retreats of Europe. It now has a third pole, and in some respects the most consequential one. In roughly two years the Gulf has produced the field’s first regulatory framework, committed its largest pool of research funding, and drawn a growing share of premium-clinic expansion. The regulatory, financial, and physical map of the industry increasingly runs through Abu Dhabi and Riyadh.

This is one of the central industry findings behind our work, and it matters well beyond the region. A shift in where a category is regulated and funded eventually changes where it is built, and which of its players AI search learns to treat as authorities.

The first rulebook for longevity medicine

In April 2025 the Department of Health Abu Dhabi, working with the Institute for Healthier Living Abu Dhabi and the Healthy Longevity Medicine Society, brought into effect the world’s first evidence-based clinical guidelines for healthy longevity medicine. For the first time a regulator defined, in clinical terms, what a healthy longevity clinic is, what it should offer, and how it should be governed. The same authority had already licensed IHLAD as the world’s first regulated healthy longevity medicine center. The group that wrote the standards was chaired by Andrea Maier of the National University of Singapore and included figures such as Eric Verdin of the Buck Institute, a signal that the framework was built with the field’s scientific mainstream rather than around it.

The significance lies in the credibility problem the guidelines address. A 2025 survey of 288 longevity clinics by the Dubai-based Detki Family and Molodost clinics found that close to 90 percent offered treatments driven more by marketing than by evidence, with only about one in ten prioritizing scientifically validated approaches. In a category that loose, a regulator drawing a clear line between evidence-based practice and everything else is the first structural correction the field has had. And it is exportable: once one regulator shows that licensing longevity facilities is workable, others have a model to copy. Abu Dhabi has pressed that advantage, launching a Declaration on Longevity and Precision Medicine at its 2025 Global Health Week and inviting other governments to sign.

A licensing regime also changes what a clinic can credibly claim. Before April 2025 any operator could call itself a longevity center, and a prospective patient had no external standard to test the claim against. A framework creates one. It gives a serious clinic a way to distinguish itself that does not depend on marketing, and it gives a skeptical patient, or a skeptical AI search platform, something concrete to weigh.

The largest pool of money in longevity science

Saudi Arabia’s Hevolution Foundation, based in Riyadh, has committed to deploying up to a billion dollars a year toward healthspan research, and has already allocated more than 400 million dollars, making it the world’s largest philanthropic funder of the field. No venture fund, family office, or government program matches that scale of dedicated, patient capital.

Funding at that scale concentrates gravity. Research programs follow the money, scientific talent follows the programs, and drug development follows the talent. The longevity-pharmaceutical pipeline of the next decade will be shaped in part by where its single largest backer sits, and that backer is now in the Gulf. Hevolution is also a different kind of funder from the ones the category has relied on. Venture capital needs an exit within a fund’s life, and private wealth is patient but rarely deployed at scale. A sovereign-backed foundation spending at this level can fund the slow, unglamorous work, the longitudinal studies and basic geroscience, that commercial money tends to skip. For context, total global healthspan-science investment reached 7.33 billion dollars in 2024, so a single Gulf funder operating at up to a billion a year is a structural force in a field that size.

The luxury map is moving south

The premium-clinic map is following the rules and the money. Clinique La Prairie, one of the oldest names in luxury longevity, is opening a longevity health resort at Amaala on Saudi Arabia’s Red Sea coast, only its second full resort outside Switzerland. It anchors a deliberate cluster: Amaala’s Triple Bay is launching from 2026 with a group of wellness-led brands including Four Seasons, Six Senses, and Equinox, positioned explicitly as a destination for health and longevity rather than ordinary luxury.

Riyadh is building its own capacity. The Longevity Wellness Hub opened a Riyadh flagship in 2026, and the Zenos Wellness Summit brought leading longevity figures to the capital in 2025. The pattern is consistent: the brands and platforms that define the high end of the category are putting physical capacity closer to the region setting its rules and funding its science. Expansion decisions of this size are made years in advance, which means the operators committing to the Gulf now reached that conclusion some time ago.

Why this matters for clinics outside the Gulf

For a clinic in the United States or Europe, the strategic question is no longer whether to engage the Gulf but how. Three consequences follow.

The Abu Dhabi standards are positioned to become a de facto global reference. A clinic operating under recognized longevity-medicine standards will say so in its content, and AI search increasingly reads alignment with a recognized framework as an authority signal. A standard that began as a local licensing requirement becomes a citation differentiator everywhere.

Capital concentration accelerates consolidation. Sovereign-scale funding speeds the development of drugs, diagnostics, and integrated care models, reshaping what every clinic can offer and what it competes against. A clinic planning its next five years against the category as it looked in 2023 is planning against a category that no longer exists.

The Gulf is also becoming a destination market for international longevity patients, which means AI search will increasingly localize toward it, with its own emerging set of cited authorities. Clinics that want a share of Gulf-origin demand will need content that AI search can surface when the question is asked from, or about, the region.

The longevity economy’s first phase was written in California and the Alps. Its next phase has a third pole that is writing the rules and signing the checks. The clinics that recognize the shift early will be the ones positioned within it.

Sources

  • Department of Health Abu Dhabi; Gulf Business; Longevity.Technology, on the April 2025 healthy longevity medicine guidelines and IHLAD licensing.
  • Khaleej Times, on the Detki Family and Molodost survey of 288 longevity clinics (2025).
  • Hevolution Foundation, on its funding commitment and the second Global Healthspan Report (2024 investment of 7.33 billion dollars).
  • AFAR; Business Today Middle East; Clinique La Prairie, on the Amaala Triple Bay openings.
  • Healthspan Economy Atlas, on the Longevity Wellness Hub and the Zenos Wellness Summit.